A potential tie-up between Bristol Myers Squibb and AstraZeneca is looking less and less like a good deal to Wall Street. After rising in premarket trading Monday, Bristol Myers stock reversed course ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

UBS has told investors that the recent slide in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares has gone too far, keeping its ...

Bristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a competitor. Late Sunday, the FT reported that the two companies have discussed a merger in recent ...

Read the original story, posted Aug. 3, below: U.K. drugmaker AstraZeneca and New Jersey-based competitor Bristol Myers Squibb are reportedly considering a tie-up that would create a pharmaceutical ...

Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.

Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused ...

AstraZeneca (AZN) tops pharmaceutical growth rankings while Bristol Myers Squibb (BMY) trails, as the two drugmakers reportedly explore a potential merger that could create one of the world's largest ...

AstraZeneca is considering a merger with Bristol Myers Squibb, potentially valued at $400 billion. Talks have occurred for several months, but no formal agreement is expected soon. AstraZeneca shares ...

Bristol Myers Squibb stock trades in the mid-$60s as investors weigh reported merger talks with AstraZeneca, Q2 2026 earnings momentum and a full-year 2026 EPS guidance range that anchors valuation ...